Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Protalix is a biopharmaceutical company developing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. The company's lead product candidate is taliglucerase alfa (prGCD) for the treatment of Gaucher disease. In November 2009, the company entered into an exclusive license and supply agreement with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, retaining rights only for Israel.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenues | $388,000 | $0 |
| Net Loss | $(31.44) million | $(22.41) million |
| Research & Development Expenses (Net) | $21.64 million | $17.40 million |
| General & Administrative Expenses | $7.14 million | $6.77 million |
| Cash and Cash Equivalents (Year End) | $81.27 million | $42.60 million |
| Total Assets | $98.67 million | $50.81 million |
| Total Liabilities | $82.79 million | $6.46 million |
| Shareholders' Equity | $15.88 million | $44.35 million |
Note: The significant increase in liabilities in 2009 is primarily due to the recording of deferred revenue from the Pfizer agreement ($65 million total upfront and milestone payments received).
Material Changes vs. Prior Period
- Revenue Recognition: The company recorded $388,000 in revenue in 2009, compared to zero in 2008. This represents the pro-rata amortization of the $65 million received from Pfizer (a $60 million upfront payment and a $5 million milestone payment) over an estimated 14-year performance period.
- Net Loss Increase: Net loss increased by approximately $9 million (40%) year-over-year, driven by increased R&D expenses related to the completion of the Phase III clinical trial for taliglucerase alfa and increased personnel costs.
- Liquidity Position: Cash and cash equivalents nearly doubled from $42.6 million in 2008 to $81.3 million in 2009, bolstered by the Pfizer payments. Net cash provided by operating activities turned positive at $44.5 million in 2009, compared to a use of $16.0 million in 2008.
- Deferred Revenue: A new line item for deferred revenue appeared on the balance sheet, totaling $64.6 million ($4.6 million current, $60.0 million long-term), reflecting the Pfizer agreement.
Guidance, Outlook, and Management Commentary
- Regulatory Status: The company filed a New Drug Application (NDA) for taliglucerase alfa with the FDA in December 2009. In January 2010, the FDA requested additional data regarding the Chemistry, Manufacturing, and Controls (CMC) section, specifically focusing on the validation of the manufacturing process. No additional clinical data was requested. The company anticipates submitting this data in the second quarter of 2010.
- Clinical Results: The pivotal Phase III clinical trial was completed in September 2009 with positive top-line results announced in October 2009. The trial met its primary endpoint (reduction in spleen volume) and secondary endpoints.
- Future Funding: Management believes existing cash and anticipated regulatory milestone payments from Pfizer are sufficient to fund operations for the foreseeable future. However, the company expects to incur substantial losses as it expands manufacturing capacity (estimated cost of $20 million) and builds a sales force for Israel.
- Risks: Key risks include the potential rejection or delay of the NDA, the ability to validate manufacturing processes, and the need for additional financing if assumptions regarding cash burn or milestone timing prove incorrect.
Investor Verification Checklist
- FDA Response Timeline: Verify the submission date of the requested CMC data to the FDA and the subsequent review timeline for the NDA.
- Manufacturing Validation: Confirm the status of the manufacturing facility upgrade and the successful completion of the validation plan required by the FDA.
- Pfizer Agreement Terms: Review the specific milestones triggering the remaining $50 million in potential payments and the definition of "net profits" for the 40% royalty share.
- Capital Expenditures: Monitor the progress and cost of the $20 million manufacturing facility expansion planned for 2010-2011.
- Israeli Tax Benefits: Verify the company's continued eligibility for "Approved Enterprise" tax exemptions and the impact of the Pfizer revenue on these benefits.